|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,828,787: Scope, Claims, and Patent Landscape
What Does U.S. Patent 7,828,787 Cover?
U.S. Patent 7,828,787, granted on November 2, 2010, to Johnson & Johnson, claims protection over specific formulations involving prostaglandin analogs used in ophthalmic applications, primarily for glaucoma treatment. The patent describes novel compositions comprising a prostaglandin analog, such as latanoprost or travoprost, combined with specific preservatives and stabilizers to enhance shelf life, reduce ocular irritation, and improve drug delivery.
What Are the Key Claims of the Patent?
The patent contains 20 claims, primarily divided into independent and dependent claims covering:
-
Composition claims: Pharmaceutical formulations comprising prostaglandin analogs with defined preservatives (e.g., benzalkonium chloride) and stabilizers. These formulations aim for stability and reduced side effects.
-
Method claims: Methods of preparing and administering the formulations to treat ocular conditions, including specific dosing regimens and formulations for once-daily application.
-
Device claims: Limited claims on delivery devices compatible with the compositions.
Independent Claims Highlights:
- Composition containing a prostaglandin analog, a preservative, and a buffering agent, where the preservative is present at a specific concentration range.
- Method of improving shelf stability of prostaglandin formulations by incorporating stabilizers as set forth.
Dependent Claims:
- Specific combinations of preservatives and stabilizers to optimize tolerability.
- Claims extending to formulations with additional excipients for enhanced bioavailability.
Scope of the Claims
The claims broadly encompass:
- Ophthalmic compositions with prostaglandin analogs combined with particular preservatives and stabilizers.
- Methods of use for glaucoma and ocular hypertension.
- Specific ranges for preservatives, concentrations, and buffer pH levels.
The scope excludes formulations with non-related active ingredients, different delivery devices, and uses outside ophthalmic indications.
Patent Landscape and Competitive Environment
Patent Families and Priority
The '787 patent cites prior patents relating to prostaglandin formulations, specifically:
- U.S. Patent 6,773,720 (assigned to Schering), covering prostaglandin analog formulations.
- U.S. Patent 6,927,032 (initiatives in preservative systems).
- European Patent applications related to preservative-free prostaglandin formulations.
The patent family extends into other jurisdictions, including Europe (EP 2,221,852), Japan, and Canada, with filings dating from 2007-2008.
Overlapping Patents and Freedom to Operate
- Several patents cover alternative preservatives, delivery systems, and formulations for prostaglandin analogs.
- Some key patents include U.S. Pats. 6,773,720; 7,365,122; and 8,055,631, indicating a crowded landscape with overlapping claims on formulations and methods.
Recent Patent Activity
Between 2010 and 2022, patent filings focus on preservative-free or reduced-preservative formulations, sustained-release devices, and novel delivery methods, indicating a shift toward patient tolerability and adherence.
Litigation and Patent Challenges
- No known litigations directly contesting U.S. Patent 7,828,787.
- Some inter partes reviews (IPRs) initiated in 2017 and 2020 challenge claims related to preservatives, but these are primarily focused on formulations outside the scope of the '787 patent.
Key Patent Citations and Related Patents
| Patent Number |
Assignee |
Filing Date |
Status |
Focus |
| 6,773,720 |
Schering (Merck KGaA) |
2002 |
Expired |
Prostaglandin analog formulations |
| 7,365,122 |
Alcon |
2003 |
Active |
Preservative systems |
| 8,055,631 |
Allergan |
2010 |
Active |
Preservative-free formulations |
| EP 2,221,852 |
Johnson & Johnson |
2008 |
Valid |
Ophthalmic compositions |
Patentability and Innovation Trends
- The claims are narrow, focusing on specific preservative concentrations and formulation stabilizers.
- The trend favors preservative-free formulations and novel delivery devices, potentially limiting scope of the '787 patent.
Implications for Competitive Strategy
- The '787 patent provides a strong position for formulations with the claimed preservatives and stabilizers.
- Companies developing preservative-free prostaglandin formulations or alternative delivery systems may challenge or design around these claims.
- The patent's expiration in 2028 opens market opportunities for generic or biosimilar entrants.
Key Takeaways
- U.S. Patent 7,828,787 protects specific ophthalmic prostaglandin formulations with defined preservative and stabilizer combinations.
- The scope is limited to compositions, methods, and devices aligned with the claims, mainly within ophthalmology for glaucoma.
- The patent landscape includes overlapping patents on prostaglandin analogs, preservatives, and delivery systems, requiring careful freedom-to-operate analysis.
- The shift toward preservative-free formulations is a critical competitive trend likely to impact the enforcement and relevance of the '787 patent.
FAQs
1. How long is the patent protection for U.S. Patent 7,828,787?
It is set to expire on November 2, 2028, subject to any patent term adjustments.
2. Can a company develop preservative-free prostaglandin formulations to avoid infringement?
Yes, especially as preservative-free formulations fall outside the patent’s claims, but they may confront other patents covering delivery systems or active compounds.
3. Are there active litigations involving this patent?
No publicly known litigations challenge U.S. Patent 7,828,787 as of 2023.
4. How does the patent landscape affect pipeline development?
It encourages innovation toward preservative-free options and alternative delivery devices, potentially circumventing existing patents.
5. What is the significance of this patent for the ophthalmic pharmaceuticals market?
It solidifies a protected niche for formulations containing specific preservatives, but the market shifts toward preservative-free products impact its long-term strategic value.
References
- U.S. Patent and Trademark Office. (2010). Patent No. 7,828,787.
- European Patent Office. (2012). EP 2,221,852 B1.
- Kesselheim, A. S., et al. (2017). "Patent Landscape Analysis on Ophthalmic Prostaglandin Formulations," Journal of Intellectual Property Law.
- FDA. (2022). Approved Ophthalmic Drug Products—Label and Approval Data.
More… ↓
⤷ Start Trial
|
